Management of Newly Diagnosed Older AML Patients Unfit for Traditional Therapy

Clinical trials in acute myeloid leukemia (AML) for the last 40 years have generally focussed on younger patients or older patients clinically judged to be fit for intensive chemotherapy. However the median age of AML is 68-70 years so there was a large “trial- neglected” population, for whom therapeutic options were not being explored. The standard of care was palliation with supportive care, and if necessary mild oral chemotherapy to control the white count, so called “Best Supportive Care” (BSC).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research